Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 70
Selected: 0
NCT IDTitle
NCT01094496A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)
NCT05029999CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
NCT03835533Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations
NCT03688178DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab
NCT04364230Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)
NCT00709462A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)
NCT04548869A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria
NCT04440943A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
NCT05349890Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
NCT05368285A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
NCT00948961A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
NCT00412828A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma
NCT04491084FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy
NCT01480479Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
NCT03068650Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut
NCT03617328Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma
NCT02302339A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
NCT01997333Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
NCT05774184A Study of CDX-0159 in Patients With Eosinophilic Esophagitis
NCT03473691Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer
NCT02270372Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer
NCT03307746A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell Lymphoma
NCT04930783NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
NCT01976585In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy
NCT03580382Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma
NCT00648102Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer
NCT01156753A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
NCT06445023A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT06727552A Study of Barzolvolimab in Patients With Atopic Dermatitis
NCT03804944Converting HR+ Breast Cancer Into an Individualized Vaccine
NCT01460134A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
NCT01465139A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers
NCT02543645A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
NCT03789097Vaccination With Flt3L, Radiation, and Poly-ICLC
NCT06650761A Phase I Study of CDX-622
NCT02284971Pilot Study of SBRT and CDX-1127 in Prostate Cancer
NCT05231122Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
NCT03067935Individual Patient Expanded Access-Glembatumumab Vedotin
NCT02642016A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors
NCT06455202A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT04538794A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
NCT02713828Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung
NCT02386111A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
NCT00704158Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer
NCT04146129A Phase 1 Study of CDX-0159
NCT00458601Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme
NCT03358719DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT02839265FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer
NCT05405660A Study of CDX-0159 in Patients With Chronic Inducible Urticaria
NCT04536077Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients